COVID-19 ‘cocktail’ therapy moves to clinical trial
A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.
The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…